Baxter and ScinoPharm Announce Exclusive Strategic Partnership for Generic Oncology Injectables

08:00 EST 28 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Arrangement includes five generic injectables used in cancer treatment, with option to add up to 15 more molecules Collaboration combines ScinoPharm’s world-class API expertise with Baxter’s diffe...

Other Sources for this Article

Baxter International Inc.
Media Contacts:
Bill Rader, (224) 948-5353
Eric Tatro, (224) 948-5353
Investor Contact:
Clare Trachtman, (224) 948-3085


More From BioPortfolio on "Baxter and ScinoPharm Announce Exclusive Strategic Partnership for Generic Oncology Injectables"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...